PARP inhibitors in ovarian cancer

被引：152

作者：

Franzese, Elisena ^{[1
]}

Centonze, Sara ^{[1
]}

Diana, Anna ^{[1
]}

Carlino, Francesca ^{[1
]}

Guerrera, Luigi Pio ^{[1
]}

Di Napoli, Marilena ^{[2
]}

De Vita, Ferdinando ^{[1
]}

Pignata, Sandro ^{[2
]}

Ciardiello, Fortunato ^{[1
]}

Orditura, Michele ^{[1
]}

机构：

[1] Luigi Vanvitelli Univ Campania, Sch Med, Dept Precis Med, Div Med Oncol, I-80131 Naples, Italy

[2] IRCCS, Ist Nazl Studio Cura Tumori Fdn G Pascale, I-80131 Naples, Italy

来源：

CANCER TREATMENT REVIEWS | 2019年 / 73卷

关键词：

Ovarian cancer; PARP inhibitors; Olaparib; Niraparib; Rucaparib; NEGATIVE BREAST-CANCER; HOMOLOGOUS RECOMBINATION; MAINTENANCE THERAPY; DOUBLE-BLIND; OPEN-LABEL; MUTATION CARRIERS; BRCA2; MUTATIONS; PHASE-I; OLAPARIB; CARCINOMA;

D O I：

10.1016/j.ctrv.2018.12.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Poly-ADP-ribose polymerase inhibitors (PARPis) are the most active and interesting therapies approved for the treatment of epithelial ovarian cancer. They have changed the clinical management of a disease characterized, in almost half of cases, by extreme genetic complexity and alteration of DNA damage repair pathways, particularly homologous recombination (HR) deficiency. In this review, we provide an updated overview of the available results of recent clinical trials on the three Food and Drug Administration and European Medicines Agency approved PARPis in ovarian cancer: olaparib, niraparib, and rucaparib. Furthermore, we anticipate the future perspective of combination regimens with antiangiogenic, immunocheckpoint inhibitors, and other biological agents as strategies to overcome resistance mechanisms, potentiate the therapeutic efficacy, and expand their clinical use in non-HR deficient tumors.

引用

页码：1 / 9

页数：9

共 50 条

[1] PARP Inhibitors in Ovarian Cancer
Mittica, Gloria
Ghisoni, Eleonora
Giannone, Gaia
Genta, Sofia
Aglietta, Massimo
Sapino, Anna
Valabrega, Giorgio
[J]. RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2018, 13 (04) : 392 - 410
[2] PARP inhibitors in ovarian cancer
David Cibula
Judith Balmaña
[J]. British Journal of Cancer, 2015, 113 : S1 - S2
[3] PARP inhibitors in ovarian cancer
Goldlust, Ian S.
Guidice, Elena
Lee, Jung-min
[J]. SEMINARS IN ONCOLOGY, 2024, 51 (1-2) : 45 - 57
[4] PARP Inhibitors in Ovarian Cancer
da Costa, Alexandre
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (16): : 1572 - 1573
[5] PARP INHIBITORS IN OVARIAN CANCER
Calvert, H.
Curtin, N.
Plummer, R.
[J]. ANNALS OF ONCOLOGY, 2008, 19 : 23 - 23
[6] PARP Inhibitors for Ovarian Cancer
不详
[J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1535): : 200 - 202
[7] PARP inhibitors in ovarian cancer
Ledermann, J. A.
[J]. ANNALS OF ONCOLOGY, 2016, 27 : 40 - 44
[8] PARP INHIBITORS IN OVARIAN CANCER THERAPY
Pisula, Agata
Sienicka, Agnieszka
Dobrowolska-Redo, Agnieszka
Kacperczyk-Bartnik, Joanna
Romejko-Wolniewicz, Ewa
[J]. PROSPECTS IN PHARMACEUTICAL SCIENCES, 2024, 22 (02): : 71 - 74
[9] PARP Inhibitors in Ovarian Cancer Treatment
Spriggs, David R.
Longo, Dan L.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22): : 2197 - 2198
[10] PARP Inhibitors in Ovarian Cancer: A Review
David M. O’Malley
Thomas C. Krivak
Nashwa Kabil
Jiefen Munley
Kathleen N. Moore
[J]. Targeted Oncology, 2023, 18 : 471 - 503

← 1 2 3 4 5 →